Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 448, 525 (2 August 2007) | doi:10.1038/448525a; Published online 1 August 2007
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
- More Challenges
- Powered by:
nature jobs
Tenure-Track Faculty Positions
- The University of Texas Southwestern Medical Center
- Dallas, TX 75390-9148 United States
Head of Production Biopharmaceuticals
- Rhein Minapharm Biogenetics
- Cairo (Egypt)
Swiss on a roll
Abstract
Smart investors who know the drugs business well are helping to make Zurich's stock market a popular place for biotechnology firms to raise money. Andrea Chipman reports.
At a time when biotechnology companies worldwide are finding it tough to raise money, the Swiss Exchange (SWX) in Zurich is proving to be an alluring financial home."It's an excellent stock market that took the initiative ten years ago to build up a biotech medical segment that makes it attractive," says Ulrich Steiner, an analyst at Swiss bank Clariden Leu in Zurich, adding that smaller biotech companies find it easier to be noticed by investors and raise their profiles in Switzerland.
To read this story in full you will need to login or make a payment (see right).
